Four out of five clinical trials fail due to recruitment challenges. While AI is projected to accelerate drug discovery by 50 percent, progress may still stall at the clinical trial stage without similar advances in patient recruitment. Traditional recruitment methods continue to surface the same participant pools, limiting enrollment reach and trial diversity. Seen & Heard Health exists to identify participants beyond these established pools, helping sponsors identify overlooked participants that traditional recruitment methods often miss. Through its purpose-built AI platform, it helps sponsors verify, recruit and onboard the difficult-to-find 15 to 20 percent of participants that often determine whether trials meet recruitment goals. Traditional recruitment methods rely on fixed channels like referral networks, patient databases, EHR and digital ads, limiting their ability to adapt to evolving eligibility criteria. Seen & Heard Health applies AI and graph analysis to public digital data to identify disease-related signals, behavioral patterns and relationships associated with harder-to-reach participant populations. The platform supports more targeted recruitment, engagement and enrollment strategies by helping sponsors identify high-potential recruitment regions, tailor outreach and activate trusted patient voices. “We have trained our AI specifically for recruiting difficult-tofind patients, representing a new front in clinical trial recruitment,” says Curtis Hougland, founder. Built over more than a decade, Seen & Heard Health’s platform is designed specifically for clinical trial recruitment. It also applies machine learning to organize unstructured public data alongside structured healthcare data..

What challenges have made integrated evidence planning harder for biopharma teams? Integrated Evidence Plans (IEPs) in biopharma have outgrown the deck-and-tracker workflows that built them. Plans fragment across Medical Affairs, Commercial, Market Access, HEOR, and Clinical Development. Real World Evidence and clinical evidence sit in separate plans. MSL insights sit unactioned in SharePoint. Missed gaps surface as failed HTA submissions, weakened payer negotiations, and prescribers who lack the data to act with confidence. EVEXA, Princeton Biopartners AI-native platform purpose-built for IEPs and Data Dissemination Plans (DDPs), brings evidence gap analysis, study prioritization, dissemination planning, and KPI tracking into a single source of truth. Why EVEXA Earned the Recognition How does EVEXA differ from broader evidence generation software platforms? Five characteristics separate EVEXA from the broader landscape. It is the only AI-native platform purpose-built for IEPs and DDPs, not a publication planner or surveillance tool retrofitted toward evidence generation. The AI is native, not bolted on: three connected agents operate as the core of the platform, producing source-cited, explainable outputs governance committees can approve. It was built by the people who do the work, developed by a consultancy with 150+ IEP and IEGP engagements behind it. It produces measurable outcomes: evidence synthesis 80 percent faster, gap identification 10x faster, IEP pre-read prep cut 70 percent. And it was built for pharma-grade governance from the first line of code, with private cloud deployment, full audit traceability, and validated data quality gates. What Makes EVEXA AI-Native: Three Core Agents Why are EVEXA’s three AI agents central to evidence lifecycle traceability? The Evidence Gap Analysis Agent continuously ingests evidence from the public scientific corpus and internal documents, structures it against asset claims and value drivers, and surfaces gaps with full source lineage in days rather than quarters. The Intelligent Decision-Making Engine scores each gap across evidence quality, severity, recency, and competitor coverage, producing a defensible composite priority score with LLM-generated rationale, plus a white space view for first-mover opportunities. Smart Assist, a conversational layer, makes the entire intelligence stack accessible in plain language with source-linked answers in seconds. The three agents feed each other in a closed loop, connecting MSL insights, gaps, study proposals, and dissemination KPIs with full traceability across the evidence lifecycle..

Pharmaceutical and biotech companies are facing increasing pressure to scale complex molecules while meeting stricter regulatory expectations, sustainability targets and supply-chain reliability requirements. Aspen API helps customers manage those pressures through integrated API development and manufacturing capabilities designed for high-complexity pharmaceutical programs. “Aspen API differentiates itself by combining deep pharmaceutical heritage with the agility and engagement of a focused CDMO partner,” says Marcella van Dinther, commercial project manager. Aspen API was formed through the combined capabilities of Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. It provides customers with Western-aligned regulatory standards, flexible GMP manufacturing and geographically diverse supply-chain support. Its facilities specialize in highly potent and technically demanding APIs including peptides, antineoplastics, hormones and biochemical extraction products. Aspen API also maintains a broad regulatory footprint supported by multiple DMFs and inspections from global health authorities. Many customers are increasingly seeking manufacturing partners capable of reducing dependence on Asian supply chains while maintaining strong regulatory reliability and uninterrupted production continuity. Aspen API positioned its European manufacturing presence and global infrastructure around those priorities..

Biomanufacturing demands precision at every turn—whether safeguarding sensitive biologics like monoclonal antibodies and live cells or ensuring accurate flow rates and overall system efficiency. Bioprocessing pumps are at the heart of this operation, entrusted with delivering fluids steadily and consistently. Yet, traditional pumps—hampered by pulsation, shear stress, and inherent inefficiencies—have historically imperiled product integrity and raised operational costs. Alphinity is changing that equation. Evolving from ARTeSYN BioSolutions, a trailblazer in valve technology, Alphinity was founded with a singular mission: to transcend the limitations of conventional peristaltic, diaphragm, and centrifugal pumps. The company’s flagship innovation, PIXER® , is a singleuse component that seamlessly merges pumping and mixing functions while adhering to Pharma 4.0 standards. “Innovation is our heartbeat at Alphinity. With PIXER® , we’re not just refining fluid management—we’re pioneering a new era in bioprocessing where precision, efficiency, and patient wellbeing converge to deliver transformative, life-saving therapies,” says Craig Vincze, Vice President & Co-Founder. PIXER®: A Breakthrough in Fluid Management Pulsation at the pump outlet is a significant challenge for bioprocessing, disrupting electronic flow sensors and causing flow rate and pressure fluctuations. PIXER® eliminates these issues, ensuring smooth, precise fluid movement while optimizing efficiency. Designed for high-value biologics, it minimizes shear stress, operates at high pressures, and efficiently handles viscous fluids. PIXER® ’s top inlet placement is a key mechanical innovation that allows direct positioning beneath a fluid reservoir, such as a bioreactor or retentate tank, in a tangential flow filtration (TFF) system. Unlike conventional pumps with side-positioned inlets, this vertical orientation leverages gravity for continuous fluid feed, enhancing suction efficiency and preventing air entrapment and cavitation—common issues in horizontal pump designs. This gravity-assisted design also reduces footprint and prevents tubing collapse under suction pressure, which is particularly beneficial for handling high-viscosity fluids or high flow rates..